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Objectives. To evaluate the efficacy of dienogest + estradiol valerate (E2V) and
gonadotrophin-releasing hormone analogue (GnRH-a) in reducing recurrence
of pain in patients with chronic pelvic pain due to laparoscopically diagnosed
and treated endometriosis. Design. Multi-center, prospective, randomized
study. Setting. Three university departments of obstetrics and gynecology in
Italy. Population. Seventy-eight women who underwent laparoscopic surgery
for endometriosis combined with chronic pelvic pain. Methods. Post-operative
administration of dienogest + E2V for 9 months (group 1) or GnRH-a
monthly for 6 months (group 2). Main outcome measures. A visual analogue
scale was used to test intensity of pain before laparoscopic surgery at 3, 6 and
9 months of follow up. A questionnaire to investigate quality of life was
administered before surgery and at 9 months of follow up. Results. The visual
analogue scale score did not show any significant differences between the two
groups (p = 0.417). The questionnaire showed an increase of scores for all
women compared with pre-surgery values, demonstrating a marked improve-
ment in quality of life and health-related satisfaction with both treatments. No
significant differences were found between the groups. The rate of apparent
endometriosis recurrence was 10.8% in group 1 and 13.7% in group 2
(p = 0.962). Conclusion. Both therapies seemed equally efficacious in prevent-
ing endometriosis-related chronic pelvic pain recurrence in the first 9 months
of follow-up.
Abbreviations: CA125, cancer antigen 125; CPP, chronic pelvic pain; E2V,
estradiol valerate; EHP, Endometriosis Health Profile; GnRH-a,
gonadotrophin-releasing hormone analogues; OC, oral contraceptive; QoL,
quality of life; VAS, visual analogue scale.
Introduction
Endometriosis is a chronic disease caused by the growth
of functional endometrium-like tissue outside the uterine
cavity, which in turn causes infertility and pelvic pain (1).
It is a common gynecological disease affecting between 2
Key Message
Dienogest + estradiol valerate as a back-up therapy
for preventing endometriosis-related pain relapse after
surgery is as effective as a gonadotrophin-releasing
hormone analogue.
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and 10% of women of reproductive age (2). Painful
symptomatology may occur during menstrual bleeding
(dysmenorrhea) and sexual intercourse (dyspareunia), or
the pain may not follow any cyclical pattern (chronic pel-
vic pain, CPP) (3). If endometriosis involves the rectum
or bladder, dyschezia or dysuria may be present (4).
However, the disease is quite complicated and due to this,
classification has evolved from a local disorder to a
chronic systemic affliction (1). For many patients, it has a
severe impact on quality of life (QoL) (5).
Laparoscopic conservative surgery may reduce painful
symptoms and improve QoL in 67–80% of patients (6),
but lesions and symptoms frequently recur within
2–5 years (7,8). The likelihood of hospital readmission
for endometriosis within 4 years after surgery for addi-
tional surgical treatment was found to be 27% (9), with
some women requiring three or more re-operations
(10). Repeated surgery is positively associated with
increased morbidity and health care costs and, in
ovarian endometriosis, with damage to the ovarian
reserve (11). Therefore, postoperative medical treatment
has been advocated to prolong the symptom-free period
and at the same time delay recurrence as long as
possible (12,13).
Gonadotrophin-releasing hormone analogues (GnRH-
a), combined oral contraceptives (OCs) or progestins are
the most frequently used hormonal treatment (12).
Although effective, most of these options are associated
with side-effects, which may affect compliance and pre-
clude long-term use. GnRH-a cause an estrogen-deficient
state (14); they also act directly on steroidogenesis and
suppress endometrial implant growth (15). After
6 months, additional therapy with OCs is recommended
to prevent the loss of bone density becoming a risk factor
for fractures (14). When compared with placebo, GnRH-
a was highly effective in a 6-month trial (16).
Since hormonal therapy is not curative, treatments
often need to be administered for years to prolong their
effects. For this reason, safe, inexpensive and well-toler-
ated drugs of known efficacy, such as OCs, were tested
(17). In some recent studies, long-term exposure to OCs
after conservative surgery for ovarian endometriosis was
associated with a major reduction of recurrences (8,12).
Moreover, since progesterone is considered the most
active drug in the OCs for the prevention of recurrence,
new progestins are continually being tested to find one
that ensures the desired results with minimal side-effects.
Two recent clinical studies in Europe and Japan have
investigated dienogest, a 19-nortestosterone derivative,
demonstrating that at 2 mg daily, this progestin effec-
tively reduces endometriosis lesions, improves QoL and
would appear to be as effective as GnRH-a in terms of
endometriosis-related pelvic pain improvement (18,19).
In addition, there are advantages in safety and tolerability,
including a reduced incidence of hypoestrogenic effects
and minimal change in bone mineral density (5). This
drug was marketed initially as an OC, co-administered
with estradiol valerate (E2V) (Qlaira, Bayer, Germany).
Recently, it has been offered individually for the treat-
ment of endometriosis (5,20).
Based on this, continuous low-dose OCs containing
dienogest + E2V were tested against GnRH-a in women
who had CPP due to pelvic endometriosis after laparo-
scopic treatment, with the primary outcome to compare
efficacy in prevention of pain recurrence and health-
related QoL for up to 9 months. A secondary outcome
was to evaluate the recurrence rate of endometriosis
lesions.
Material and methods
A multi-center prospective randomized study on patients
who had undergone conservative surgery for CPP due to
endometriosis was conducted in the Departments of
Obstetrics and Gynecology of the Universities of Naples,
Messina and Palermo, which are all referral centers for
the diagnosis and management of endometriotic disease.
Permission was obtained from the Local Institutional
Review Boards before the study began (approval date 17
July 2009) and each patient gave their signed informed
consent for recruitment. Study conduct and analysis was
performed following the CONSORT criteria (www.equa-
tor-network.org) but the study was not registered in a
clinical trials database at the time.
Inclusion criteria were age between 18 and 45 years, no
immediate desire for offspring, surgical and histological
confirmation of endometriotic disease, a visual analogue
scale (VAS, see below) score >40 before surgery and no
hormone therapy in the 3 months preceding surgery. The
exclusion criteria were absence of precise details of the
operation or histologic diagnosis of endometriosis, usual
contraindications to OCs or GnRH-a, chronic use of
alcohol or drugs that affect cognitive function, psychiatric
disorders, concomitant neoplastic disease or chronic pel-
vic inflammatory disease.
Demographic and historical data were collected. A clin-
ical gynecological examination with pelvic and vaginal
ultrasound and measurement of serum cancer antigen
125 (CA-125) were performed in all patients before lapa-
roscopic surgery. To assess severity of the symptoms, all
patients were invited to score the intensity of pain with a
VAS score to evaluate dysmenorrhea, dyspareunia and
non-menstrual pelvic pain subjectively on a scale from 0
to 100 (0 = no pain, 100 = unbearable pain). The VAS
score is a validated measure of endometriosis-related pain
and is widely used in clinical trials (21).
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In addition, all women completed an Endometriosis
Health Profile (EHP) questionnaire, i.e. the short form
EHP-5, used to measure effects that endometriosis may
have on women’s lives, with scores rated on a scale from
0 to 10 (worst health to best health). It is a recommended
instrument to assess health status when conducting
clinical trials associated with endometriosis (22). Data
on the VAS and questionnaire scores are reported as
mean  standard deviation.
All procedures were performed by expert surgeons
(Level II of the Italian Society of Gynecologic En-
doscopy). Staging of endometriosis was carried out
according to the revised American Fertility Society (rAFS)
classification (23). Laparoscopic surgery was performed
on all enrolled patients. At histopathological evaluation,
samples confirmed the presence of endometriosis in all
cases. During laparoscopy, superficial peritoneal endometri-
osis lesions, ovarian lesions, one bladder nodule, utero-
sacral ligament nodules, recto-vaginal nodules and all
adhesions were identified and removed (Table 1). No bowel
resection was performed. No intraoperative complications
occurred and no laparotomy conversion was needed.
A random sequence using SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA), which returns a random value
from a Bernoulli distribution with the specified prob-
ability parameter (0.5) was generated. Patients were
placed in alphabetical order and then, using the random
sequence previously generated, each patient was assigned
to one of the two treatment groups, dienogest + E2V
(group 1, n = 39) or the GnRH-a (group 2, n = 39).
On discharge after laparoscopy, group 1 patients
received OCs with dienogest + E2V (multiphasic pill with
2 mg of E2V for 22 days + 2 mg of dienogest for 5 days
and 3 mg for 17 days; the first two and the last four pills
containing only E2V or placebo were removed) (Qlaira,
Bayer, Germany). Group 2 patients received GnRH-a, i.e.
leuprorelin acetate 3.75 mg, one dose every 30 days
(Enantone, Takeda, Italy). Patients in group 1 repeated
this administration of OCs without interruption for
9 months. In group 2, the GnRH-a dose was repeated
every 30 days for 6 months.
Follow-up visits were at 3, 6 and 9 months after treat-
ment. At each follow-up, clinical assessment, vaginal and
rectal examination and transvaginal ultrasonography were
performed to evaluate potential endometriosis recurrence
and VAS score assessed to evaluate the presence or
severity of pelvic pain. Recurrence was defined, for conve-
nience, as the presence of an endometriosis lesion, visible
with transvaginal ultrasound scanning or felt at vaginal
examination. Highly qualified sonographers with exten-
sive experience in the detection of endometriotic lesions
performed all scans. We defined ovarian endometriotic
cysts according to the diagnostic ultrasound criteria es-
tablished by Mais et al. (24).
At the 9-month follow up, the serum level of CA-125
was measured and patients’ QoL tested using the same
questionnaire as in the pretreatment phase.
Statistical analysis
Statistical analysis was performed with SPSS for Win-
dows. Differences between two data series were analyzed
by the Mann–Whitney test, and differences between cate-
gorical groups by Fisher’s exact test. A log-rank test was
performed to assess differences in rate of recurrent endo-
metriosis between different treatments. Statistical signifi-
cance was set at p < 0.05. At alpha = 0.05, the study
power was 80% with a difference of 7  11 (OC therapy)
and 16  20 (GnRH-a therapy) in the mean VAS score.
Results
An overview of the study is shown in Figure 1 in a flow
diagram. Characteristics of the patients at baseline are
Table 1. Laparoscopic surgical procedures among the randomized women.
Laparoscopic surgery
Group 1 (n = 39) Group 2 (n = 39)
p-valuen % n %
Unilateral cystectomy 19 48.7 22 56.4 0.65
Bilateral cystectomy 10 25.6 7 17.9 0.584
Rectovaginal nodule removal 2 5.1 1 2.6 1
Uterosacral ligament nodule removal 2 5.1 4 10.3 0.675
Bladder nodule removal 0 0 1 2.6 1
Ablation of peritoneal endometriosis 33 84.6 35 89.7 0.737
Thin and tough adhesion removal 36 92.3 38 97.4 0.615
Unilateral salpingoophorectomy 4 10.3 3 7.7 1
Bilateral salpingoophorectomy 0 1 2.6 1
Group 1: dienogest + estradiol valerate (E2V); Group 2: leuprorelin acetate (GnRH-a). Statistical analysis was performed using Fisher’s exact test.
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reported in Table 2. There were no significant differences
between the groups in terms of age (p = 0.532), body
mass index (p = 0.398), AFS stages (p = 0.847), VAS
scores (p = 0.269) or CA-125 (p = 0.32) before treatment.
Three patients (7.7%) in group 1 and five (12.8%) in
group 2 did not complete the study: seven for causes
unrelated to the study and one for side-effects attributable
to OC therapy.
Visual analogue scale data did not show significant dif-
ferences in any of the follow-up visits between the two
groups (p = 0.417) (Figure 2) and were lower in the first
follow up than before surgery in both group 1
(p < 0.0001) and group 2 (p < 0.001).
Recurrent disease was represented in all cases by an
ovarian cyst, unilateral in five cases and bilateral in only
one case (Table 3). The ultrasound characteristics of these
cysts were typical of endometrioma (unilocular, with a
regular profile, “ground glass” appearance, with a thick
wall and absence of internal papillary projections)
(24,25). The mean size of the cysts was 2.6 (0.6) cm. In
only two cases were the cysts associated with pelvic pain.
We could not exclude misdiagnosis of minimal endome-
triotic foci as these are not detectable by ultrasound or by
vaginal gynecologic exploration. No sign of endometriosis
was present at the first follow up in any of the women
who subsequently reported a recurrence of the disease.
Assessed for eligibility (n = 85)
Excluded (n = 7)
♦ Not meeting inclusion criteria (n = 5)
♦ Declined to participate (n = 1)
♦ Other reasons (n = 0)
Analysed (n = 36)
♦ Excluded from analysis (give reasons) (n = 0)
Lost to follow-up (give reasons) (n = 3)
Discontinued intervention (give reasons) (n = 1 
for side effects attributable to oc therapy; 2 for 
causes unrelated to the study)
Allocated to intervention (n = 39)
♦ Received allocated intervention (n = 39)
♦ Did not receive allocated intervention (give 
reasons) (n = 0)
Lost to follow-up (give reasons) (n = 5)
Discontinued intervention (give reasons) (n = 5 
for causes unrelated to the study)
Allocated to intervention (n = 39)
♦ Received allocated intervention (n = 39)
♦ Did not receive allocated intervention (give 
reasons) (n = 0)
Analysed (n = 34)
♦ Excluded from analysis (give reasons) (n = 0)
Randomized (n = 78)
Figure 1. CONSORT flow diagram showing a study overview.
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For this reason, we considered the cyst a “recurrence”
and not “a persistence” of the disease.
Rates of cumulative recurrence were 10.8% in group 1
and 13.7% in group 2, but this difference was not statisti-
cally significant between the groups (p = 0.962). Endome-
triosis recurrence and side-effects at each follow-up are
reported in Table 3.
At the 9-month follow up, the questionnaire results
showed a considerable increase of scores for all women
compared with before surgery, demonstrating an
improvement in the QoL and an equal health-related sat-
isfaction with both treatments. In group 1, the mean
score before treatment was 4.2  1.9 and after treatment
8.6  2; in group 2 the mean score before treatment was
4.9  2 and after treatment 9.1  1.8. No differences
were found between the two groups at baseline and at
9-month follow up, respectively (p = 0.123 and p = 0.391).
CA-125 mean value at 9 months was 22.3  16.9 in
group 1 and 25.1  19.7 in group 2 (p = 0.541).
Discussion
The current study was an attempt to find the best solu-
tion, in terms of efficacy, to prevent and/or decrease the
risk of CPP due to pelvic endometriosis after laparoscopic
treatment, comparing the effect of OCs with dienogest
and a GnRH-a. The study also evaluated the recurrence
rate of endometriosis lesions.
Approximately 40–45% of patients have a relapse of
the disease that engenders further surgery (26). There is
worldwide concern regarding the risk of repeated opera-
tions for an endometrioma as a major cause of ovarian
insufficiency (27). For this reason, it is important to base
post-surgery therapeutic strategies on factors which affect
the natural course of the disease and its tendency to reap-
pear (7).
The American Congress of Obstetricians and Gynecolo-
gists Practice Bulletin suggests that the true recurrence
rate must be even higher than the rate generally stated, as
most publications report symptomatic disease only (28).
In addition, there is much variance in the reported
cumulative recurrence rate among published studies. The
definition of recurrence also varies (subjective feeling of
pain or more objective clinical/instrumental measures)
with type of endometriosis, methods of surgery, disease
severity, and surgeon’s skills being among the known or
potential factors that may influence recurrence risk.
The rationale for postoperative treatment is to perform
complete eradication of the lesions that could not be sur-
gically removed, or to treat microscopic foci that may not
have been evident to the surgeon, as well as to prevent
iatrogenic dissemination of endometriotic cells (29). But
as medical treatment is suppressive and not extirpative
therapy, pain may recur after discontinuation. Therefore,
long-term treatment is needed and consideration has been
given not only to efficacy, but also to the safety and toler-
ability of the treatment options available.
The European Society of Human Reproduction and
Embryology guidelines recommend suppression of ovar-
ian function with hormonal therapy with level A–B evi-
dence (30). Gonadotrophin-releasing hormone analogues
combined OCs or progestins are the options most usually
adopted. Vast differences in treatment modality, types of
endometriosis, length of follow up and outcome measure-
ments preclude a meaningful systematic review of their
use.
GnRH-a have long been used in the treatment of CPP
related to endometriosis, and administration for 6 months
Table 2. Demographic characteristics of the patients at baseline.
Group 1 (n = 39) Group 2 (n = 39)
p-valueMean  SD Mean  SD
Age (years) 31.2  2.6 30.5  2.5 0.532
BMI (kg/m2) 21.7  2.3 22.4  2.1 0.398
rAFS stage (n)
I 2 3 0.847
II 6 7
III 23 20
IV 8 9
VAS score 48.4  18.7 53.6  20.2 0.269
CA-125 (U/mL) 97.8  31.4 89  28.6 0.32
All data are expressed as mean  SD except AFS stage, which is
expressed in number of patients (n). Statistical analysis was performed
using the Mann–Whitney test. Group 1: dienogest + estradiol valerate
(E2V); Group 2: leuprorelin acetate (GnRH-a).
BMI, body mass index; rAFS, Revised American Fertility Society Score.
Figure 2. Comparison of visual analogue scale (VAS) scores in group
1 (dienogest + estradiol valerate) and group 2 (leuprorelin acetate
3.75 mg). IQR, interquartile range.
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(which is the maximum recommended treatment duration
when no estrogen add-back therapy is used) appears to
improve the duration of pain relief (14). In our study we
compared GnRH-a to OCs containing dienogest and we
found a similar effectiveness in reducing pelvic pain associ-
ated with endometriosis up to 9 months of follow up,
although long-term GnRH-a tolerability would be unlikely
if the treatment were to be continued for longer (14). Pre-
operative characteristics of the patients had no significant
influence on subsequent pain improvement. Pain was
evaluated with a VAS score, one of the most utilized tests
in clinical research even if it is not fully objective (31);
it has, however, the advantage of simplicity, is language-
independent and is easily understood by most patients. The
VAS score was assessed at the beginning of the study and
again at all follow-up visits; there was a considerable
increase of scores and thus a marked improvement in QoL
and health-related satisfaction with both treatments. We
used a short form of the EHP questionnaire which has
proved to be useful in a previous Italian study. However, it
must be kept in mind that the Italian version of EHP-5 has
not been validated and therefore data obtained with it
cannot be compared with data obtained with validated
EHP-5 results in other languages, such as the original
British version (32). During administration of the two hor-
monal therapies, at the sixth month of follow up we found
GnRH-a and the dienogest OCs to be similar with regard
to the side-effects of headache, vaginal dryness and weight
gain. The only significant differences were in vasomotor
symptoms, decreased libido and discomfort due to amen-
orrhea. Prolonged administration of GnRH-a is limited
by undesired effects on bone mineral density and climac-
teric symptoms. In this perspective, continuous OCs are
probably the better choice to prevent effects of estrogen
deprivation. The effects of surgery and post-surgical medi-
cal treatment could not be dissociated from the study
design, but increased patient satisfaction can be regarded as
important and may lead to better treatment compliance in
the long run.
A randomized comparative trial showed that post-
operative treatment after surgery for pelvic endometriosis,
either with GnRH-a or with continuous monophasic
OCs, at an early follow up of 12 months was more effec-
tive than placebo in terms of relief of endometriosis-asso-
ciated pain. No data were available on recurrence of
asymptomatic disease (33). In addition, in another ran-
domized multi-center trial, GnRH-a and dienogest dem-
onstrated the same significant improvements of pelvic
pain due to endometriosis at 6 months of follow up (5).
Unfortunately, although effective, GnRH-a therapy is
expensive and associated with side-effects (16) due to the
prolonged hypoestrogenic state it causes. Therefore, long-
term use, in the absence of add-back therapy, is pre-
cluded.
Oral contraceptives can provide a better option in terms
of safety, tolerability and cost, and can be administered for
long periods (8,12). They may induce atrophy of the peri-
toneal endometriotic implants (34) and reduce disease-
related pain (35). Moreover, OCs reduce retrograde men-
strual bleeding and inhibit ovulation, both of which are
considered etiopathogenetic factors for endometriosis
(7,8). Progestogens contained in OCs also prevent implan-
tation and growth of regurgitated endometrium by inhibit-
ing matrix metalloproteinase expression and angiogenesis,
which reduce the inflammatory state and immune response
(36). All these reported mechanisms have been analyzed in
Table 3. Endometriosis recurrence and side-effects at 3, 6 and 9 months of follow up.
Endometriosis recurrence
3-month follow up 6-month follow up 9-month follow up
Group 1
(n = 39)
Group 2
(n = 39)
p
Group 1
(n = 36)
Group 2
(n = 35)
p
Group 1
(n = 36)
Group
2
(n = 34)
pn % n % n % n % n % n %
Unilateral cyst – – – 1 1 1 2 1 1
Bilateral cyst – – – – – – – 1 0.486
Other recurrence – – – – – – – – –
Side-effects
Headache 6 15 4 10 0.737 7 19 6 17 1 7 19 1 3 0.056
Decreased libido 10 26 7 18 0.584 11 31 9 26 0.793 12 33 4 12 0.046
Spotting 6 15 2 5 0.263 5 14 1 3 0.199 2 6 0 0 0.493
Vaginal dryness 5 13 8 21 0.545 7 19 10 29 0.415 8 22 1 3 0.028
Vasomotor symptoms 0 0 7 18 0.012 0 0 10 29 <0.0001 0 0 1 3 0.486
Discomfort from amenorrhea 10 26 15 38 0.332 10 28 17 49 0.09 10 28 0 0 0.001
Weight gain 1 3 2 5 1 2 6 4 11 0.429 2 6 1 3 1
Group 1: dienogest + estradiol valerate (E2V); Group 2: leuprorelin acetate (GnRH-a). Statistical analysis was performed using Fisher’s exact test.
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recent studies that appraised the validity of long-term
administration of OCs in preventing ovarian endometri-
oma (12,37) and the recurrence of painful symptoms (38).
Vercellini et al. reported that patients who always used
OCs had an absolute risk reduction of recurrence of 47%
when compared with never users (8). No differences
between available formulations were found among the var-
ious kinds of OCs (12,39). A comparative study between
postoperative administration of OCs containing dienogest
or a levonorgestrel intrauterine system (LNG-IUS) for
prevention of pain relapse and disease recurrence in
endometriosis patients, demonstrated better efficacy of
OCs in reducing pelvic pain at 12 months of follow up (2).
The progestogen component of the “combined pill” is
widely considered the active therapeutic drug in treating
or preventing endometriosis (12). In recent years, the
attention of clinicians has been focused on dienogest,
which is currently the only steroidal treatment marketed
in most of Europe. Dienogest reduces endometriotic
lesions by creating a local progestogenic environment,
suppressing the systemic estrogen level moderately (32).
Some studies have demonstrated that it is as effective as
GnRH-a therapy in terms of endometriosis-related pelvic
pain improvement (19) and also offers advantages in
terms of safety and tolerability (5). The reasoning behind
using an estradiol-based combined pill in our study,
when endometriosis is clearly an estrogen-sensitive
disease, is that it also provides contraception, which, offi-
cially, dienogest does not. Furthermore, the control cycle
is sometimes better, with less spotting. It is fair to point
out that endometriosis benefits from non-fluctuating hor-
monal situations, such as pregnancy, so we assumed that
the presence of a small amount of estrogen was not
harmful.
Recurrence has been defined in varying ways in many
published studies, making it difficult to estimate recur-
rence rates. Vignali et al. (40) reported that 3- and 5-year
recurrence rates were 20.5 and 43.5%, respectively, for
pain, but the corresponding rates for clinical recurrence
were 9 and 28% (40). Overall, it appears that recurrence
rates for pain or dysmenorrhea are higher than for clini-
cal recurrences as defined by more objective and verifiable
criteria such as sonography. We found a 10–15% rate of
recurrence of endometriosis lesions at 9 months of follow
up but with no significant differences between the two
treatment modules used, in spite of GnRH-a administra-
tion for only a 6-month period and OCs for 9 months.
This circumstance might be explained by the effect of
GnRH-a on endometriosis, which may last up to several
months after suspension (38). In only two cases was the
recurrence of an endometrioma associated with pelvic
pain, thus confirming that having a detectable clinical
recurrence is not a prerequisite for the presence of
symptoms, and that symptoms may precede or succeed
clinical recurrence.
A potential bias of this study was that women were
only followed to 9 months, since long-term recurrence of
endometriosis is possible, but data are lacking on long-
term symptom profiles. Based on our study results we
consider dienogest + E2V a valid therapy for preventing
endometriosis-related pain relapse after surgery, with an
efficacy similar to that of GnRH-a.
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